Background: Ocular toxicities in children with neuroblastoma receiving GD-2 antibody therapy such as dinutuximab are uncommon. The objectives of this case study are to highlight the presentation and treatment of two ocular toxicities: pupillary palsy affecting... ...

请注册登录后继续浏览